CN110367533A - A kind of alimentation composition that treating diabetes and its application - Google Patents
A kind of alimentation composition that treating diabetes and its application Download PDFInfo
- Publication number
- CN110367533A CN110367533A CN201910758810.6A CN201910758810A CN110367533A CN 110367533 A CN110367533 A CN 110367533A CN 201910758810 A CN201910758810 A CN 201910758810A CN 110367533 A CN110367533 A CN 110367533A
- Authority
- CN
- China
- Prior art keywords
- parts
- alimentation composition
- diabetes
- treatment
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 92
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 43
- 241000414067 Inonotus obliquus Species 0.000 claims abstract description 19
- 108010073771 Soybean Proteins Proteins 0.000 claims abstract description 15
- 235000019710 soybean protein Nutrition 0.000 claims abstract description 15
- 235000016709 nutrition Nutrition 0.000 claims abstract description 5
- 230000035764 nutrition Effects 0.000 claims abstract description 5
- 239000004615 ingredient Substances 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 239000011782 vitamin Substances 0.000 claims description 35
- 229940088594 vitamin Drugs 0.000 claims description 29
- 229930003231 vitamin Natural products 0.000 claims description 29
- 235000013343 vitamin Nutrition 0.000 claims description 29
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 29
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 20
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 16
- 229920001202 Inulin Polymers 0.000 claims description 14
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 14
- 229940029339 inulin Drugs 0.000 claims description 14
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 13
- 210000000582 semen Anatomy 0.000 claims description 12
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 11
- 235000013734 beta-carotene Nutrition 0.000 claims description 11
- 239000011648 beta-carotene Substances 0.000 claims description 11
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 10
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 10
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 claims description 10
- 229930003268 Vitamin C Natural products 0.000 claims description 10
- 229940083466 soybean lecithin Drugs 0.000 claims description 10
- 235000019154 vitamin C Nutrition 0.000 claims description 10
- 239000011718 vitamin C Substances 0.000 claims description 10
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 9
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 9
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 9
- 229960002747 betacarotene Drugs 0.000 claims description 9
- 229960003966 nicotinamide Drugs 0.000 claims description 9
- 235000005152 nicotinamide Nutrition 0.000 claims description 9
- 239000011570 nicotinamide Substances 0.000 claims description 9
- 235000008935 nutritious Nutrition 0.000 claims description 9
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 8
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 8
- 239000004376 Sucralose Substances 0.000 claims description 8
- 229960000304 folic acid Drugs 0.000 claims description 8
- 235000019152 folic acid Nutrition 0.000 claims description 8
- 239000011724 folic acid Substances 0.000 claims description 8
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 8
- 235000019408 sucralose Nutrition 0.000 claims description 8
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 7
- 229960002079 calcium pantothenate Drugs 0.000 claims description 7
- 244000068988 Glycine max Species 0.000 claims description 6
- 235000010469 Glycine max Nutrition 0.000 claims description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- 229930014669 anthocyanidin Natural products 0.000 claims description 5
- 150000001452 anthocyanidin derivatives Chemical class 0.000 claims description 5
- 235000008758 anthocyanidins Nutrition 0.000 claims description 5
- 239000011575 calcium Substances 0.000 claims description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- 235000021283 resveratrol Nutrition 0.000 claims description 5
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 4
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 229910052742 iron Inorganic materials 0.000 claims description 4
- 235000012661 lycopene Nutrition 0.000 claims description 4
- 229940016667 resveratrol Drugs 0.000 claims description 4
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 3
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 3
- 239000001751 lycopene Substances 0.000 claims description 3
- 229960004999 lycopene Drugs 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- 239000011574 phosphorus Substances 0.000 claims description 3
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 150000001579 beta-carotenes Chemical class 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 235000019161 pantothenic acid Nutrition 0.000 claims description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 claims 1
- 240000003768 Solanum lycopersicum Species 0.000 claims 1
- 229940067606 lecithin Drugs 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 29
- 239000008280 blood Substances 0.000 abstract description 29
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 24
- 239000008103 glucose Substances 0.000 abstract description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 14
- 102000004877 Insulin Human genes 0.000 abstract description 12
- 108090001061 Insulin Proteins 0.000 abstract description 12
- 229940125396 insulin Drugs 0.000 abstract description 12
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 9
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 8
- 235000005911 diet Nutrition 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 8
- 235000013305 food Nutrition 0.000 abstract description 7
- 239000000047 product Substances 0.000 abstract description 7
- 230000000378 dietary effect Effects 0.000 abstract description 5
- 230000037213 diet Effects 0.000 abstract description 3
- 208000000668 Chronic Pancreatitis Diseases 0.000 abstract description 2
- 206010033649 Pancreatitis chronic Diseases 0.000 abstract description 2
- 230000004203 pancreatic function Effects 0.000 abstract description 2
- 239000013589 supplement Substances 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 11
- 210000000496 pancreas Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 description 6
- FEZWOUWWJOYMLT-DSRCUDDDSA-M cobalt;[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7,1 Chemical compound [Co].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FEZWOUWWJOYMLT-DSRCUDDDSA-M 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 5
- 240000007594 Oryza sativa Species 0.000 description 5
- 235000007164 Oryza sativa Nutrition 0.000 description 5
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 5
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 5
- 235000013339 cereals Nutrition 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 235000009566 rice Nutrition 0.000 description 5
- 235000019155 vitamin A Nutrition 0.000 description 5
- 239000011719 vitamin A Substances 0.000 description 5
- 229940045997 vitamin a Drugs 0.000 description 5
- 239000000428 dust Substances 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 3
- 244000302512 Momordica charantia Species 0.000 description 3
- 235000009811 Momordica charantia Nutrition 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229930185803 charantin Natural products 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000002641 glycemic effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 description 2
- 235000018185 Betula X alpestris Nutrition 0.000 description 2
- 235000018212 Betula X uliginosa Nutrition 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 244000298479 Cichorium intybus Species 0.000 description 2
- 235000007542 Cichorium intybus Nutrition 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 240000008892 Helianthus tuberosus Species 0.000 description 2
- 235000003230 Helianthus tuberosus Nutrition 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- 240000003394 Malpighia glabra Species 0.000 description 2
- 235000014837 Malpighia glabra Nutrition 0.000 description 2
- 235000009812 Momordica cochinchinensis Nutrition 0.000 description 2
- 235000018365 Momordica dioica Nutrition 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 239000003538 oral antidiabetic agent Substances 0.000 description 2
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241000432824 Asparagus densiflorus Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- 241000699662 Cricetomys gambianus Species 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000747105 Fuscoporia Species 0.000 description 1
- 102100036264 Glucose-6-phosphatase catalytic subunit 1 Human genes 0.000 description 1
- 101710099339 Glucose-6-phosphatase catalytic subunit 1 Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 150000000992 L-arabinoses Chemical class 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 150000002187 fatty acyl carnitines Chemical class 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000002430 glycogenolytic effect Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 229940118199 levulan Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 150000002664 lycopenes Chemical class 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229940005657 pyrophosphoric acid Drugs 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000000837 restrainer Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to field of food, specifically disclose a kind of alimentation composition for treating diabetes and its application in the dietary product of preparation treatment diabetes, the alimentation composition includes the ingredient of following parts by weight: 25-45 parts of soybean protein isolate, 3-15 parts and 3-10 parts of Inonotus obliquus extract of Bitter Melon P.E, Inonotus obliquus extract in alimentation composition can be used in treating or preventing chronic pancreatitis, Bitter Melon P.E can reduce the blood glucose of diabetic, soybean protein isolate can be improved the insulin level of body, above-mentioned collocation can not only supplement the nutrition outside diets of diabetic patients, insulin resistance and pancreatic functions obstacle can also be improved, cooperation dietary management has apparent effect to blood glucose is reduced.
Description
Technical field
The present invention relates to field of food, and in particular to a kind of alimentation composition for treating diabetes and the nutrient combination
Application of the object in the dietary product of preparation treatment diabetes.
Background technique
Diabetes are a kind of common endocrine metabolism diseases, when pancreas can not produce enough insulin or human body
When insulin caused by can not effectively utilizing, it just will appear diabetes.Lethality, disability rate and the medical expense of diabetes
Public health problem that is higher, being faced for current various countries.The data of the World Health Organization show that 2016, diabetes were estimated
Meter directly contributes 1,600,000 death, 2012, separately has 2,200,000 death to be attributable to hyperglycemia；18 years old global or more adult sugar
Urinate sick illness rate from 4.7% in 1980 increase to 2014 8.5%；Type 2 Diabetes In China patient has 1.2 hundred million within 2017
People, wherein 52.3% patient is not diagnosed.The above true explanation, as the improvement of people's living standards, diabetic has
The trend to increase sharply.
Currently, being mostly following several for the Western medicine for the treatment of diabetes: melbine class, insulin type, sulfonylureas and
Alpha-glucosidase restrainer.The diabetic of 50% or more developed country receives insulin therapy, and domestic this compares
Example is 10% or so.Diabetic then gradually can need to merge using it first since the treatment of single oral hypoglycemic agents
The oral hypoglycemic agents of its type, but to reach the control target of ideal blood glucose, there is still a need for starting pancreas islet by most of patient
Extract for treating.Namely the supplement of external insulin or the activation of itself pancreas islet are the key that treatment diabetes.
Diabetes B is as caused by insulin resistance and islet beta cell function obstacle.Insulin resistance refers to normal agent
The insulin of amount generates a kind of state for being lower than natural biological effect, refers to that the sensibility of insulin and reactivity drop in target tissue
It is low.Islet beta cell function obstacle will lead to insulin secretion reduction or insufficient, so as to cause blood glucose rise.Wherein obesity
It is to generate the most important risk factors of insulin resistance.
Therefore in addition to finding new drug, exploitation toxic side effect is few, there is the Hyperglycemic health care of protective effect to eat to beta Cell of islet
Product have become an important research direction.The existing product for diabetic's dietotherapy mostly based on low sugar, high microsteping,
It is conceived to reduction blood glucose target, and has ignored the application for improving insulin resistance in treatment diabetes.
Summary of the invention
For the defects in the prior art, the present invention provides a kind of alimentation composition for treating diabetes, and long-term consumption should
Composition can be effectively improved insulin resistance problem, while assist repairing the function of pancreas.
To achieve the above object, the technical scheme adopted by the invention is as follows:
A kind of alimentation composition for treating diabetes, the alimentation composition include the ingredient of following parts by weight: soybean point
- 45 parts from protein 25,3-15 parts of Bitter Melon P.E and 3-10 parts of Inonotus obliquus extract.
Preferably, brown containing soybean protein isolate 30-40 parts, 6-10 parts of Bitter Melon P.E and birch in the alimentation composition
5-10 parts of linteus extract.
Inonotus obliquus (Inonotus obliquus (Pers.Fr.) Pilat) is also referred to as birch young pilose antler or inonotus obliquus, belongs to porous
Cordycepps, brown transverse hole fungus category, are that one kind treasures medicinal fungi.Inonotus obliquus exists without apparent toxic side effect, Inonotus obliquus extract
Antitumor, anti-inflammatory, reducing blood lipid, hypoglycemic and raising immunity etc. have good curative effect, meanwhile, in anti-oxidant and conciliation machine
Body metabolism etc. also has certain effect.The principal monosaccharides and mass fraction for forming Fuscoporia obliqua polysaccharide are successively: grape
Sugared 10.75%, galactolipin 2.44%, arabinose 0.53%, mannose 0.48%, glycosidic bond is mainly α type, and contains acidity
Polysaccharide.
Charantin is mainly contained in Bitter Melon P.E, also contains balsampear seed glycosides, eliminating containing high energy element, bitter gourd polypeptide and citrulling
Equal amino acid.Peptide material in Bitter Melon P.E has the function of reducing blood glucose, especially Charantin, have and insulin phase
As act on, can reduce fasting blood-glucose, and blood glucose normally keep stablizing afterwards it is lasting.
Preferably, the alimentation composition is also containing in soybean lecithin, nutritious yeast, inulin, Semen Phaseoli extract
It is at least one.
Further, the alimentation composition contains 5-10 parts of soybean lecithins, 6-12 parts of nutritious yeasts, 3-18 portions of chrysanthemums
Powder, 3-8 part Semen Phaseoli extract.
Inulin is also known as synanthrin, is a kind of levulan that D- fructofuranose is polymerized through 1,2- glycosidic bond.Mainly from jerusalem artichoke
It is extracted in (Helianthus tuberosus) or witloof (Cichorium intybus L.) stem tuber.Inulin is day in nature
So one of existing soluble dietary fiber, can extend the energy supply time of carbohydrate, and do not significantly improve in human body
Blood glucose level, metabolism do not need insulin, help to reduce diabetes patient to the dependence of insulin, are conducive to control blood glucose water
It is flat.Inulin can reduce serum total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C), improve high-density lipoprotein/
The ratio of low-density lipoprotein.Rich in substances such as selenium, chromium in nutritious yeast, be conducive to repair impaired Stem Cells.
Preferably, the alimentation composition further includes containing zinc, calcium, magnesium, phosphorus, 0.9-1.2 parts of compound of iron.
Compound containing zinc, calcium, magnesium, phosphorus, iron is specially calcium oxide, calcium carbonate, magnesia, calcium bicarbonate and pyrophosphoric acid
Iron, element needed for these compounds are capable of providing cell metabolism.
Preferably, the alimentation composition also contains at least one of niacinamide, folic acid, calcium pantothenate, beta carotene.
Further, the alimentation composition contain 0.04-0.07 parts of niacinamide, 0.0005-0.002 parts of folic acid,
0.008-0.02 parts of calcium pantothenates, 0.7-1.5 parts of beta carotenes.
Preferably, the alimentation composition also contains vitamin mixtures, and the vitamin mixtures at least contain day
Right vitamin C.Contain 2.7-3.5 parts of the natural vitamin C in the alimentation composition.
Further, the vitamin mixtures also contain 0.001-0.003 parts of vitamin As, 0.004-0.01 parts of dimension lifes
Plain B1,
0.003-0.01 parts of vitamin B2s, 0.003-0.01 parts of vitamin B6s, 10-6-10-5 parts of vitamin B12s, 10-6-
At least one of 10-5 vitamine D3 and 0.04-0.07 parts of vitamin Es.The anti-inflammatory that vitamin mixtures can enhance cell is made
With conducive to the reparation of cell.
Preferably, the alimentation composition also contains at least one of L-arabinose and L-carnitine-L-tartrate.
Further, the alimentation composition contains 5-12 parts of L-arabinoses and 1.5-4 parts of L-carnitine-L-tartrates.
L-carnitine-L-tartrate is the stable form of L-carnitine, and L-carnitine is necessary to one of body fat metabolic process
Coenzyme, be used as carrier, by, long chain fatty acids be transported in film outside mitochondrial membrane in the form of fatty acyl carnitine, online grain
The Medium Culture of body carries out beta oxidation, to achieve the effect that degradation fat.And L-arabinose has the function of that reduction is glycemic.
Preferably, the alimentation composition is also containing at least two in resveratrol, natural lycopene and anthocyanidin.
Further, the alimentation composition contain 0.004-0.01 parts of resveratrols, 0.5-2 parts of natural lycopenes and
1.5-4 parts of anthocyanidin.Resveratrol, natural lycopene and anthocyanidin have oxidation resistant effect, have for repair cell
Play the role of positive.
Preferably, the alimentation composition also contains 0.02-0.05 parts according to parts by weight of Sucralose.Sucralose
Addition can improve the mouthfeel of alimentation composition.
It is particularly preferred that the ingredient that the alimentation composition contains following parts by weight: 38 parts of soybean protein isolate, balsam pear mention
Take 9 parts of object, 5 parts of Inonotus obliquus extract, 8 parts of soybean lecithin, 9 parts of nutritious yeast, 12 parts of inulin, 4 parts of Semen Phaseoli extract,
C3 parts of natural vitamin, 1 part of beta carotene, 8 parts of L-arabinose, 2.5 parts of L-carnitine-L-tartrate, Sucralose 0.03
Part.
The carbon water content of alimentation composition of the invention is low, although containing certain sugariness, heat is low, and contains
It is low glycemic, it had not only reduced the burden of pancreas but also had not influenced its validity to control insulin resistance.
The present invention also provides the alimentation compositions of above-mentioned treatment diabetes in the dietary product of preparation treatment diabetes
Application.
The beneficial effects of the present invention are embodied in:
Contain soybean protein isolate, Bitter Melon P.E and Inonotus obliquus in the alimentation composition for the treatment of diabetes of the invention
Extract, wherein the polysaccharide component in Inonotus obliquus extract can be used in treating or preventing chronic pancreatitis, effectively increase pancreas
The content of superoxide dismutase in gland reduces the accumulative of malonaldehyde, the content of amylase and lactic dehydrogenase is effectively reduced；
Bitter Melon P.E improves sugar tolerance and drop by promoting hepatic glycogen synthesis, reducing hepatic glycogenolytic and reconcile body glycometabolism and realize
Blood glucose can be effectively reduced the postprandial blood sugar or fasting blood-glucose of hyperglycemia person or diabetes B patient；Soybean protein isolate can
The insulin level of body is improved, G-6-Pase activity is reduced, reduces serum and liver blood lipid level, improves antioxygen
Change enzymatic activity.This alimentation composition is eaten for a long time, cooperates dietary management, has to the level for reducing blood glucose and obviously makees
With.
Specific embodiment
The following examples are only intended to illustrate the technical solution of the present invention more clearly, therefore is only used as example, and cannot
It is limited the scope of the invention with this.
It should be noted that unless otherwise indicated, technical term or scientific term used in this application should be this hair
The ordinary meaning that bright one of ordinary skill in the art are understood.
The each component source of the alimentation composition for the treatment of diabetes of the invention is commercially available to be obtained, wherein
Protein content in soybean protein isolate is 90% or more, is purchased from this Science and Technology Ltd. of Wuhan Kano；
Charantin weight content > 10% in Bitter Melon P.E is purchased from Xi'an asparagus fern Biotechnology Co., Ltd；
Inonotus obliquus extract is purchased from Hangzhou Zhong Zhikang mushroom Bioisystech Co., Ltd；
Nutritious yeast is purchased from the gloomy bioengineering Co., Ltd in Shandong hundred；
Inulin is purchased from Xi'an legendary god of farming Biotechnology Co., Ltd；
Weight content >=20% of protein in Semen Phaseoli extract is purchased from Shenzhen Zheng Yuan molecule Science and Technology Ltd.；
Soybean lecithin is purchased from Anhui Le Shi Food Co., Ltd；
Natural vitamin C is mainly provided by acerola concentrate concentration powder, and the Vitamin C content of acerola concentrate concentration powder is greater than
17%, it is purchased from Tianfeng Biological Science & Technology Co., Ltd., Xi'an.
It should be noted that raw material used in the present invention is food-grade.
Embodiment 1
Weigh 38g soybean protein isolate, 9g Bitter Melon P.E, 5g Inonotus obliquus extract, 8g soybean lecithin, 9g nutrition
Yeast, 12g inulin, 4g Semen Phaseoli extract, 1.6mg vitamin A, 5mg vitamin B1,5mg vitamin B2,5mg vitamin B6,
7.2 μ g vitamin B12s, 4 μ g vitamine D3s, 52mg parts of vitamin Es, 3g natural vitamin C, 52mg niacinamide, 0.8mg folic acid,
10mg calcium pantothenate, 1g beta carotene, 8g L-arabinose, 2.5g L-carnitine-L-tartrate, 0.03g Sucralose, mix
It closes uniformly, obtains alimentation composition.The food grade plastic packaging bag for meeting sanitary condition of obtained alimentation composition is stored,
Every bag contains 20g alimentation composition.
Embodiment 2
Weigh 25g soybean protein isolate, 6g Bitter Melon P.E, 10g Inonotus obliquus extract, 10g soybean lecithin, 12g
Nutritious yeast, 18g inulin, 5g Semen Phaseoli extract, 2.7mg vitamin A, 8mg vitamin B1,8mg vitamin B2,5mg dimension life
Plain B6,7.2 μ g vitamin B12s, 4 μ g vitamine D3s, 52mg parts of vitamin Es, 3.5g natural vitamin C, 52mg niacinamide, 15mg
The trichlorine of folic acid, 20mg calcium pantothenate, 1.5g beta carotene, 5g L-arabinose, 3.5g L-carnitine-L-tartrate, 0.03g
Sucrose is uniformly mixed, obtains alimentation composition.The obtained alimentation composition food grade plastic for meeting sanitary condition is packed
Bag storage, every bag contains 20g alimentation composition.
Embodiment 3
Weigh 45g soybean protein isolate, 14g Bitter Melon P.E, 3g Inonotus obliquus extract, 5g soybean lecithin, 6g battalion
Support yeast, 3g inulin, 8g Semen Phaseoli extract, 1.6mg vitamin A, 5mg vitamin B1,5mg vitamin B2,5mg
Vitamin B6,7.2 μ g vitamin B12s, 4 μ g vitamine D3s, 52mg parts of vitamin Es, 2.8g natural vitamin C,
52mg niacinamide, 0.8mg folic acid, 10mg calcium pantothenate, 1.2g beta carotene, 11g L-arabinose, 1.5g L-carnitine wine
The Sucralose of stone hydrochlorate, 0.03g is uniformly mixed, obtains alimentation composition.By obtained alimentation composition with meeting hygiene one
The food grade plastic packaging bag of part stores, and every bag contains 20g alimentation composition.
Comparative example 1
Itself the difference from embodiment 1 is that: the weight of Bitter Melon P.E is 1g, and the weight of soybean protein isolate is 60g, group
The total weight for closing object is constant, and each component concrete content is as follows.
Weigh 60g soybean protein isolate, 1g Bitter Melon P.E, 5g Inonotus obliquus extract, 5g soybean lecithin, 6g nutrition
Yeast, 8g inulin, 3g Semen Phaseoli extract, 1.6mg vitamin A, 5mg vitamin B1,5mg vitamin B2,5mg vitamin B6,
7.2 μ g vitamin B12s, 4 μ g vitamine D3s, 52mg parts of vitamin Es, 3g natural vitamin C, 52mg niacinamide, 0.8mg folic acid,
10mg calcium pantothenate, 1g beta carotene, 5g L-arabinose, 2.5g L-carnitine-L-tartrate, 0.03g Sucralose, mix
It closes and uniformly obtains alimentation composition.The food grade plastic packaging bag for meeting sanitary condition of obtained alimentation composition is stored,
Every bag contains 20g alimentation composition.
Comparative example 2
Itself the difference from embodiment 1 is that: soybean protein isolate is replaced with to the defatted bean-dregs powder of soybean.
Weigh 38g soybean defatted bean-dregs powder, 5g Bitter Melon P.E, 5g Inonotus obliquus extract, 8g soybean lecithin, 9g battalion
Support yeast, 12g inulin, 4g Semen Phaseoli extract, 1.6mg vitamin A, 5mg vitamin B1,5mg vitamin B2,5mg vitamin
B6,7.2 μ g vitamin B12s, 4 μ g vitamine D3s, 52mg parts of vitamin Es, 3g natural vitamin C, 52mg niacinamide, 0.8mg leaf
The trichlorine sugarcane of acid, 10mg calcium pantothenate, 1g beta carotene, 8g L-arabinose, 2.5g L-carnitine-L-tartrate, 0.03g
Sugar sieves with 100 mesh sieve soybean defatted bean-dregs powder, and then the component spare with other weighings is uniformly mixed to obtain alimentation composition.
By the food grade plastic packaging bag storage for meeting sanitary condition of obtained alimentation composition, every bag contains 20g alimentation composition.
The alimentation composition for the treatment diabetes that embodiment provides is detected:
Selecting 6 week old health male Wistar rat of SPF grade, (rat and feed are by Chinese Academy of Medical Sciences's animal reproduction
Center provides), weight (150 ± 10) g.Rat is injected twice using streptozotocin by the dosage of daily 60mg/kg, and rat is just
Normal diet (the normal diet substance of rat is grain dust), the 7th day for injecting streptozotocin, after Rat Fast 5h, tail vein
Measuring blood sugar of blood extracting value, choosing cause rat 60 of hyperglycemia, as diabetes B rat model, rat are randomly divided into 6
Group.
Test group: taking the alimentation composition of 1 bag of embodiment 1-3 that pure water 10mL is added to obtain experimental group mixture respectively, will be real
It tests group mixture and mixes to obtain test group rice paste with 20g grain dust, three groups of rats are filled respectively after tail vein measuring blood sugar of blood extracting value
Stomach contains the rice paste of the alimentation composition of embodiment 1-3.
Control group: taking the alimentation composition of 1 bag of comparative example 1-2 that pure water 10mL is added to obtain control group mixture respectively, will be right
Control group rice paste is mixed to obtain with 20g grain dust according to group mixture, a blank group is separately set, i.e., adds 10mL physiology in 20g grain dust
Salt water；The rice paste and control group rice of three groups of rat oral gavage comparative example 1-2 are pasted respectively after tail vein measuring blood sugar of blood extracting value.
The stomach-filling amount of alimentation composition is 2g/kg weight, every half an hour tail vein measuring blood sugar of blood extracting value after stomach-filling.
As a result as shown in table 1 below.
Influence (mmol/L) of 1 alimentation composition of table to rat blood sugar
| Group | 0min | 30min | 60min | 90min | 120min |
| Embodiment 1 | 14.78 | 18.39 | 16.85 | 15.25 | 14.79 |
| Embodiment 2 | 14.71 | 18.08 | 16.65 | 15.16 | 14.86 |
| Embodiment 3 | 14.65 | 19.05 | 17.02 | 15.34 | 15.11 |
| Comparative example 1 | 14.68 | 22.89 | 20.12 | 18.03 | 16.95 |
| Comparative example 2 | 14.80 | 21.45 | 19.32 | 17.69 | 16.55 |
| Blank group | 14.73 | 24.05 | 23.12 | 21.86 | 20.16 |
As shown in Table 1, there was no significant difference (P > 0.05) for the blood sugar test of each group rat before testing, through stomach-filling test group
And after the alimentation composition of control group, each group rat blood sugar value rise of test group is lower, and blood glucose reduction speed is fast,
And although the alimentation composition of control group can also reduce blood glucose, it is slower to reduce speed, illustrates alimentation composition of the invention
Blood glucose can be effectively reduced.
Alimentation composition of the invention is the extra-nutrition object outside diets of diabetic patients, is particularly suitable for diabetes B
Patient.
Alimentation composition of the invention is taken while keeping on a diet, blood glucose can be substantially reduced in one week, be used
Behind of the invention alimentation composition one month, because the complication that diabetes cause can also be improved.Compared to existing dietotherapy
Product, the present invention starts with from insulin resistance and improvement pancreatic functions are solved, rather than is conceived to the product of low sugar, high microsteping,
Therefore, although containing certain sugar in composition of the invention, the carbon water contained is low, and glycemic index is low, can reduce pancreas
Dirty burden, while Stem Cells are supplemented or provided with nutrition and is repaired.
Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention., rather than its limitations；To the greatest extent
Pipe present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that: its according to
So be possible to modify the technical solutions described in the foregoing embodiments, or to some or all of the technical features into
Row equivalent replacement；And these are modified or replaceed, various embodiments of the present invention technology that it does not separate the essence of the corresponding technical solution
The range of scheme should all cover within the scope of the claims and the description of the invention.
Claims (9)
1. a kind of alimentation composition for treating diabetes, it is characterised in that: the alimentation composition include following parts by weight at
Point: 25-45 parts of soybean protein isolate, 3-15 parts of Bitter Melon P.E and 3-10 parts of Inonotus obliquus extract.
2. the alimentation composition for the treatment of diabetes according to claim 1, which is characterized in that the alimentation composition also contains
There are at least one of soybean lecithin, nutritious yeast, inulin, Semen Phaseoli extract；Contain soybean in the alimentation composition
5-10 parts of lecithin, 6-12 parts of nutritious yeast, 3-18 parts of inulin, 3-8 parts of Semen Phaseoli extract.
3. the alimentation composition for the treatment of diabetes according to claim 2, which is characterized in that the alimentation composition also wraps
It includes containing zinc, calcium, magnesium, phosphorus, 0.9-1.2 parts of compound of iron；It is red that the alimentation composition also contains resveratrol, natural tomato
At least two in element and anthocyanidin.
4. the alimentation composition for the treatment of diabetes according to claim 2, which is characterized in that the alimentation composition also contains
There are at least one of niacinamide, folic acid, calcium pantothenate, beta carotene；Contain resveratrol in the alimentation composition
0.004-0.01 parts, 0.5-2 parts of natural lycopene, 1.5-4 parts of anthocyanidin；The alimentation composition also contains vitamin mixing
Object, and the vitamin mixtures at least contain natural vitamin C.
5. the alimentation composition for the treatment of diabetes according to claim 4, which is characterized in that the alimentation composition contains
0.04-0.07 parts of niacinamide, 0.0005-0.002 parts of folic acid, 0.008-0.02 parts of calcium pantothenates, 0.7-1.5 parts of beta carotenes.
6. the alimentation composition for the treatment of diabetes according to claim 2, which is characterized in that the alimentation composition also contains
There are at least one of L-arabinose and L-carnitine-L-tartrate；Contain the L-arabinose in the alimentation composition
5-12 parts；Contain described L-carnitine-L-tartrate 1.5-4 parts in the alimentation composition.
7. the alimentation composition for the treatment of diabetes described in -6 any one according to claim 1, which is characterized in that the nutrition
Composition also contains 0.02-0.05 parts according to parts by weight of Sucralose.
8. the alimentation composition for the treatment of diabetes according to claim 2, which is characterized in that the alimentation composition contains
The ingredient of following parts by weight: 38 parts of soybean protein isolate, 9 parts of Bitter Melon P.E, 5 parts of Inonotus obliquus extract, soybean lecithin 8
Part, 9 parts of nutritious yeast, 12 parts of inulin, 4 parts of Semen Phaseoli extract, C3 parts of natural vitamin, 1 part of beta carotene, L- are Arabic
Sugared 8 parts, 2.5 parts of L-carnitine-L-tartrate, 0.03 part of Sucralose.
9. the alimentation composition for the treatment of diabetes described in claim 1-8 any one is produced in the dietotherapy of preparation treatment diabetes
Application in product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910758810.6A CN110367533A (en) | 2019-08-16 | 2019-08-16 | A kind of alimentation composition that treating diabetes and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910758810.6A CN110367533A (en) | 2019-08-16 | 2019-08-16 | A kind of alimentation composition that treating diabetes and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110367533A true CN110367533A (en) | 2019-10-25 |
Family
ID=68259571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910758810.6A Pending CN110367533A (en) | 2019-08-16 | 2019-08-16 | A kind of alimentation composition that treating diabetes and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110367533A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060114600A (en) * | 2005-05-02 | 2006-11-07 | 주식회사 닥터엔팜 | Inonotus obliquus extract having an antidiabetic activity and a composition comprising the same as an effective ingredient |
| CN101849973A (en) * | 2010-06-11 | 2010-10-06 | 天津大学 | Total triterpenoid extract of inonotus obliquus with hypoglycemic function and pharmaceutical preparation thereof |
| CN101953442A (en) * | 2009-12-23 | 2011-01-26 | 济南圣泉唐和唐生物科技有限公司 | Health care product with function of reducing blood sugar |
| CN104187624A (en) * | 2014-08-07 | 2014-12-10 | 逯明福 | Comprehensive nutrition powder and preparation method thereof |
| CN108813590A (en) * | 2018-05-31 | 2018-11-16 | 广东省农业科学院蚕业与农产品加工研究所 | A kind of low GI formula food of suitable diabetic and preparation method thereof |
-
2019
- 2019-08-16 CN CN201910758810.6A patent/CN110367533A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060114600A (en) * | 2005-05-02 | 2006-11-07 | 주식회사 닥터엔팜 | Inonotus obliquus extract having an antidiabetic activity and a composition comprising the same as an effective ingredient |
| CN101953442A (en) * | 2009-12-23 | 2011-01-26 | 济南圣泉唐和唐生物科技有限公司 | Health care product with function of reducing blood sugar |
| CN101849973A (en) * | 2010-06-11 | 2010-10-06 | 天津大学 | Total triterpenoid extract of inonotus obliquus with hypoglycemic function and pharmaceutical preparation thereof |
| CN104187624A (en) * | 2014-08-07 | 2014-12-10 | 逯明福 | Comprehensive nutrition powder and preparation method thereof |
| CN108813590A (en) * | 2018-05-31 | 2018-11-16 | 广东省农业科学院蚕业与农产品加工研究所 | A kind of low GI formula food of suitable diabetic and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 膳书堂文化编: "《糖尿病特效疗法 新版》", 31 July 2017 * |
| 贾辉等: "抗氧化剂对2型糖尿病治疗效果的分析", 《中国处方药》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101953442B (en) | Health care product with function of reducing blood sugar | |
| Jali et al. | Efficacy of value added foxtail millet therapeutic food in the management of diabetes and dyslipidamea in type 2 diabetic patients | |
| de Queiroz et al. | Effect of the yellow passion fruit peel flour (Passiflora edulis f. flavicarpa deg.) in insulin sensitivity in type 2 diabetes mellitus patients | |
| Kochhar et al. | Effect of supplementation of traditional medicinal plants on blood glucose in non–insulin-dependent diabetics: A pilot study | |
| TWI331019B (en) | Therapeutic compositions | |
| CN110338412A (en) | The composition and its preparation of niacinamide-containing mononucleotide and ice plant and application | |
| CN102526478B (en) | Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar | |
| CN106912960A (en) | A kind of hypoglycemia healthcare food and preparation method thereof | |
| CN109745359A (en) | Be conducive to keep blood glucose balance and prevent diabetes and its composition of complication and preparation method thereof | |
| EP3574912B1 (en) | Composition for treating diabetic disease | |
| RU2283124C1 (en) | Biologically active preparation based on marine vegetable raw | |
| CN110367533A (en) | A kind of alimentation composition that treating diabetes and its application | |
| CN104000877A (en) | Blood glucose reducing composition and application thereof | |
| CN101524153A (en) | Health-care wheat flour beneficial for diabetes patients | |
| CN111214641B (en) | Traditional Chinese medicine preparation for treating diabetes | |
| CN108812051B (en) | Cordyceps militaris culture method | |
| CN100413425C (en) | Diet fiber composition with blood lipid-reducing blood sugar-decreasing functions and its production method | |
| Anwar et al. | Antidiabetic Activities of Fenugreek (Trigonella Foenum-Graecum) Seeds | |
| Arora et al. | Advanced drug delivery system in the treatment of hyperglycemia and hypoglycemia | |
| CN113785957A (en) | Sugar-free nutritional meal replacement food | |
| TWI698244B (en) | Use of a combination of small-molecule fucoidan and fucoxanthin for preparing a composition for improving non-alcoholic fatty liver | |
| Momin et al. | MANAGEMENT OF DIABETES MELLITUS: A SYSTEMATIC REVIEW. | |
| Wang et al. | Multiplexing detection and measurement of diabetes biomarkers in mice treated with different concentrations of Kappaphycus alvarezii extract | |
| CN104971146A (en) | Jackfruit powder with blood sugar and blood fat regulating function and preparation method of jackfruit powder | |
| CN1224350C (en) | Blood-sugar-regulating functional health-care food and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191025 |
|
| RJ01 | Rejection of invention patent application after publication |